Hi Allen- Thanks for providing further information about Dr. Kramer. I particularly enjoyed reading, "Practitioners and the Pharmaceutical Industry ". As someone who lives with a pharmaceutical sales rep and who has many friends who are physicians I get to hear both sides of this debate fairly frequently. I think that this article by Kramer puts things in a reasonable perspective.
All the best, -Don. Allen Esterson said: > On 24 April I wrote, quoting Bill Scott first: > >> On April 22 Bill Scott wrote: >> >> > Dr. Kramer is a well known advocate of polypharmacy, the giving of >> multiple drugs to alleviate disorders when single drugs have not >> been effective. I have not looked up his connections to the drug >> companies but I am sure he is well funded by them. His disclaimer as >> to funding relates only to this particular message within which he >> reports no specific results of research. I invite anyone to inform >> me if I am wrong. >> >> Maybe I�m missing something, but if Bill has not looked up Dr Thomas >> Kramer�s connections to any drug companies, on what grounds can he be >> �sure� that Kramer is well funded by them? > > Bill Scott replied: > >> I apologize for "being sure". I strongly suspect. I should look for >> the evidence before being sure. Perhaps, if I can find the time, I >> will do so and report back. Thanks for the correction. >> >> Bill Scott > > I�ve checked out a number of articles by Thomas A. M. Kramer, who is > Clinical Associate Professor of Psychiatry, Northwestern University, > Chicago. A message he posted on the AAMC REPORTER website may be of > interest: > > Association of American Medical Colleges REPORTER > http://www.aamc.org/newsroom/reporter/july01/respond.htm > > Q. Should there be systems in place to educate students and residents on > appropriate interactions with pharmaceuticals? If so, what should they > be? > > I think such education would be very helpful to medical trainees. It > should put these companies marketing efforts in context: how much money > is at stake, what their options are (i.e., what they can and cannot say > or do), and what they hope to accomplish. Pharmaceutical representatives > often encourage physicians and trainees to think of their companies as > benevolent "foundations," and they are anything but. This must be made > clear early in medical education. > > Thomas A.M. Kramer, M.D. > Senior Vice President > American Board of Psychiatry and Neurology Inc. > > See also: > Practitioners and the Pharmaceutical Industry > http://consultapsi.com/noticias/medicos_laborat.htm > > Allen Esterson > Former lecturer, Science Department > Southwark College, London > [EMAIL PROTECTED] > > http://www.human-nature.com/esterson/index.html > http://www.butterfliesandwheels.com/articleprint.php?num=10 > > --- > You are currently subscribed to tips as: [EMAIL PROTECTED] > To unsubscribe send a blank email to > [EMAIL PROTECTED] -- --- You are currently subscribed to tips as: [EMAIL PROTECTED] To unsubscribe send a blank email to [EMAIL PROTECTED]
